Letter to the Editor.... IgA nephropathy in a pediatric patient after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine
The Pfizer-BioNTech vaccine (BNT162b2 mRNA) against coronavirus disease 2019 (COVID-19) was granted the US Food and Drug Administration’s emergency use authorization in December 2020 for individuals aged ≥ 16 years; this was extended to include children aged 12 to 15 years on May 10, 2021. Few cases of IgA nephropathy (IgAN) flare-up have been reported, showing macroscopic hematuria, following the second dose of COVID-19 vaccine in adult and pediatric patients. , , , ,  Herein, we report the first case globally of a pediatric patient with IgAN presenting with macroscopic hematuria < 24 h after the first dose of Pfizer-BioNTech vaccine was given to the patient on Friday, 6th August 2021. The patient had no history suggestive of previous COVID-19 infection before vaccination, nor had he suffered any history of reactions to any vaccinations. See Table 1 for clinical information. We conducted further tests; On 31st, August 2021: Yellow colour, hazy appearance, trace protein, RBC: 286/ul (up to 2). On 6th, January 2022: Amber colour, hazy appearance, negative protein, RBC: 160/ul (up to 2). Hence, recent tests showed that microscopic hematuria still persisted but had been reducing.
Abdel-Qader, Derar H.
Alkhatatbeh, Issa Hazza
Al Meslamani, Ahmad Z.
Elmusa, Reem A.